Neues bei Kopfschmerzen 2006

Zusammenfassung

Neue Untersuchungen zur Epidemiologie von Kopfschmerzen zeigen jetzt auch an größeren Populationen eine Assoziation der Migräne mit und ohne Aura mit Depression und Angsterkrankungen. Neu ist eine eindeutige Assoziation zwischen Migräne und Übergewicht, eine Häufung von Fibromyalgiesyndromen bei Frauen mit Migräne, eine erhöhte Prävalenz von Synkopen bei Migränepatienten und häufigere gastrointestinale Beschwerden. Der Zusammenhang zwischen offenem Foramen ovale (PFO) und Migräne mit Aura beruht wahrscheinlich auf einer gemeinsamen genetischen Disposition. Die erste randomisierte Studie zum Schirmchenverschluss eines PFO bei Migränepatienten verlief negativ. Eine neue Studie zeigte, dass nichtsteroidale Antirheumatika wie Diclofenac in löslicher Form deutlich besser wirken als in Tablettenform. Zwei weitere Studien belegen die Schwierigkeiten, die Wirksamkeit von Triptanen bei Jugendlichen und Heranwachsenden zu belegen. Dies beruht auf der hohen Plazeboantwortrate bei Jugendlichen. Neue Erkenntnisse gibt es zum möglichen Wirkungsmechanismus von Migräneprophylaktika. In Tierexperimenten konnte gezeigt werden, dass eine Langzeitgabe von Betablockern, Antiepileptika, trizyklischen Antidepressiva und Serotoninantagonisten zu einer Erniedrigung der Schwelle für eine kortikale spreading depression führt. Zwei Studien zur Akupunktur zeigten, dass Akupunktur genauso wirksam ist wie Scheinakupunktur und einer klassischen medikamentösen Prophylaxe nicht überlegen ist.

Abstract

Recent studies on the epidemiology of migraine have shown, in a large population, an association between migraine, depression and anxiety disorders. New comorbidities with migraine include obesity, fibromyalgia (in women with migraine), syncope and gastrointestinal disturbances. The association between migraine with aura and patent foramen ovale (PFO) is due to the shared inheritance of both conditions. A randomised trial in migraine patients with PFO comparing transcutaneous shunt occlusion versus a sham procedure failed with regard to the primary endpoint (cure of migraine). A recent study showed that soluble diclofenac is more effective than the same dose in a normal tablet. It still remains difficult to show the efficacy of triptans in children and adolescents. Part of this difficulty has to do with the very high placebo response in this age group. Animal experiments were able to elucidate a possible mode of action of drugs used for migraine prevention. Long-term treatment with beta-blockers, calcium channel blockers and antiepileptics increased the threshold to provoke cortical spreading depression in rats. Short-term treatment, however, had no effect. Two large-scale studies on acupuncture for the prevention of migraine showed that Chinese acupuncture is as effective as sham acupuncture and that both are as effective as medical therapy.

Literatur

• 1 Lipton R B, Hemelsky S W, Kolodner K N. et al . Migraine, quality of life and depression. A population-based case-control study.  Neurology. 2000;  55 629-635
• 2 Breslau N, Davis G C. Migraine, major depression and panic disorder: a prospective epidemiologic study of young adults.  Cephalalgia. 1992;  12 85-90
• 3 Radat F, Swendsen J. Psychiatric comorbidity in migraine: a review.  Cephalalgia. 2005;  25 165-178
• 4 Oedegaard K J, Neckelmann D, Mykletun A. et al . Migraine with and without aura: association with depression and anxiety disorder in a population-based study. The HUNT Study.  Cephalalgia. 2006;  26 1-6
• 5 Bigal M E, Liberman J N, Lipton R B. Obesity and migraine: a population study.  Neurology. 2006;  66 545-550
• 6 Ifergane G, Buskila D, Simiseshvely N. et al . Prevalence of fibromyalgia syndrome in migraine patients.  Cephalalgia. 2006;  26 451-456
• 7 Kruit M, Buchem M van, Hofman P. et al . Migraine as a risk factor for subclinical brain lesions.  JAMA. 2004;  291 427-434
• 8 Thijs R D, Kruit M C, Buchem M A van. et al . Syncope in migraine: the population-based CAMERA study.  Neurology. 2006;  66 1034-1037
• 9 Kurth T, Holtmann G, Neufang-Huber J. et al . Prevalence of unexplained upper abdominal symptoms in patients with migraine.  Cephalalgia. 2006;  26 506-510
• 10 Aurora S K, Kori S H, Barrodale P. et al . Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack.  Headache. 2006;  46 57-63
• 11 Kurth T, Slomke M A, Kase C S. et al . Migraine, headache, and the risk of stroke in women. A prospective study.  JAMA. 2006;  296 283-291
• 12 Sette M Del, Angeli S, Leandri M. et al . Migraine with aura and right-to-left shunt on transcranial Doppler: a case-control study.  Cerebrovasc Dis. 1998;  8 327-330
• 13 Sztajzel R, Genoud D, Roth S. et al . Patent foramen ovale, a possible cause of symptomatic migraine: a study of 74 patients with acute ischemic stroke.  Cerebrovasc Dis. 2002;  13 102-106
• 14 Diener H C, Weimar C, Katsarava Z. Patent foramen ovale: paradoxical connection to migraine and stroke.  Curr Opin Neurology. 2005;  18 299-304
• 15 Schwerzmann M, Nedeltchev K, Lagger F. et al . Prevalence and size of directly detected patent foramen ovale in migraine with aura.  Neurology. 2005;  65 1415-1418
• 16 Wammes-van der Heijden E A, Tijssen C C, Egberts A C. Right-to-left shunt and migraine: the strength of the relationship.  Cephalalgia. 2006;  26 208-213
• 17 Wilmshurst P T, Pearson M J, Nightingale S. et al . Inheritance of persistent foramen ovale and atrial septal defects and the relationship to familial migraine with aura.  Heart. 2004;  90 1245-1247
• 18 Anzola G P, Frisoni G B, Morandi E. et al . Shunt-associated migraine responds favorably to atrial septal repair: a case-control study.  Stroke. 2006;  37 430-434
• 19 Reisman M, Christofferson R D, Jesurum J. et al . Migraine headache relief after transcatheter closure of patent foramen ovale.  J Am Coll Cardiol. 2005;  45 493-495
• 20 Mortelmans K, Post M, Thijs V. et al . The influence of percutaneous atrial septal defect closure on the occurrence of migraine.  Eur Heart J. 2005;  26 1533-1537
• 21 Azarbal B, Tobis J, Suh W. et al . Association of interatrial shunts and migraine headaches: impact of transcatheter closure.  J Am Coll Cardiol. 2005;  45 489-492
• 22 Schwerzmann M, Wiher S, Nedeltchev K. et al . Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks.  Neurology. 2004;  62 1399-1401
• 23 Post M, Thijs V, Herroelen L, Budts W. Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine.  Neurology. 2004;  62 1439-1440
• 24 Onorato E, Melzi G, Casilli F. et al . Patent foramen ovale with paradoxical embolism: mid-term results of transcatheter closure in 256 patients.  J Interv Cardiol. 2003;  16 43-50
• 25 Morandi E, Anzola G P, Angeli S. et al . Transcatheder closure of patent foramen ovale: a new migraine treatment?.  J Interv Cardiol. 2003;  16 39-42
• 26 Diener H, Limmroth V, Fritsche G. et al . Therapie der Migräneattacke und Migräneprophylaxe. Leitlinie der Deutschen Gesellschaft für Neurologie und der Deutschen Migräne- und Kopfschmerzgesellschaft. In: Diener H, für die Kommission Leitlinien der DGN (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie. 3. Auflage. Stuttgart; Thieme 2005: 494-508
• 27 Diener H C, Montagna P, Gacs G. et al . Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo.  Cephalalgia. 2006;  26 537-547
• 28 Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against development of cutaneous allodynia.  Ann Neurol. 2004;  55 19-26
• 29 Linde M, Mellberg A, Dahlof C. Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack.  Cephalalgia. 2006;  26 113-121
• 30 Brandes J L, Kudrow D, Cady R. et al . Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing.  Cephalalgia. 2005;  25 735-742
• 31 Scholpp J, Schellenberg R, Moeckesch B, Banik N. Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan.  Cephalalgia. 2004;  24 925-933
• 32 Klapper J, Lucas C, Rosjo O, Charlesworth B. on behalf of the ZODIAC study group . Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild.  Cephalalgia. 2004;  24 918-924
• 33 Cady R K, Sheftell F, Lipton R B. et al . Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials.  Clinical Therapeutics. 2000;  22 1035-1048
• 34 Dahloef C G. Infrequent or non-response to oral sumatriptan does not predict response to other triptans-review of four trials.  Cephalalgia. 2006;  26 98-106
• 35 Landy S H, McGinnis J E, McDonald S A. Pilot study evaluating preference for 3-mg versus 6-mg subcutaneous sumatriptan.  Headache. 2005;  45 346-349
• 36 Winner P, Lewis D, Visser H. et al . Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study.  Headache. 2002;  42 49-55
• 37 Visser W H, Winner P, Strohmaier K. et al . Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies.  Headache. 2004;  44 891-899
• 38 Lewis D, Ashwal S, Hershey A. et al . Practice parameter: pharmacological treatment of migraine headache in children and adolescents: Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society.  Neurology. 2004;  63 2215-2224
• 39 Rothner A D, Wasiewski W, Winner P. et al . Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents.  Headache. 2006;  46 101-109
• 40 Winner P, Rothner A D, Wooten J D. et al . Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study.  Headache. 2006;  46 212-222
• 41 Kavuk I, Weimar C, Kim B. et al . One-year prevalence and socio-cultural aspects of chronic headache in Turkish immigrants and German natives.  Cephalalgia. 2006;  26 1177-1181
• 42 Meskunas C A, Tepper S J, Rapoport A M. et al . Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period.  Headache. 2006;  46 766-772
• 43 Brandes J, Saper J, Diamond M. et al . Topiramate for migraine prevention: a randomized controlled trial.  JAMA. 2004;  291 965-973
• 44 Diener H, Tfelt-Hansen P, Dahlöf C. et al . Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control.  J Neurol. 2004;  251 943-950
• 45 Mathew N T, Kailasam J, Meadors L. Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate.  Headache. 2002;  42 796-803
• 46 Ayata C, Jin H, Kudo C. et al . Suppression of cortical spreading depression in migraine prophylaxis.  Ann Neurol. 2006;  59 652-661
• 47 Linde K, Streng A, Jurgens S. et al . Acupuncture for patients with migraine: a randomized controlled trial.  JAMA. 2005;  293 2118-2125
• 48 Diener H C, Kronfeld K, Boewing G. et al . Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial.  Lancet Neurol. 2006;  5 310-316
• 49 Molsberger A F, Boewing G, Diener H C. et al . Designing an acupuncture study: the nationwide, randomized, controlled, german acupuncture trials on migraine and tension-type headache.  J Altern Complement Med. 2006;  12 237-245
• 50 Zeeberg P, Olesen J, Jensen R. Efficacy of multidisciplinary treatment in a tertiary referral headache centre.  Cephalalgia. 2005;  25 1159-1167